TruLite Health secures $7m in Series A funding to combat clinical bias

TAGS

In a major move to advance health equity, TruLite Health, an industry leader in health equity solutions, has successfully closed a $7 million Series A funding round. Osage Venture Partners spearheaded the investment, which also featured contributions from Ensemble Innovation Ventures, Xcellerant Ventures, and multiple existing seed investors. The newly acquired funds will be utilized to accelerate the commercial expansion of TruLite Health and meet the rapidly growing market demand.

Truity Platform Targets Clinical Bias at Point of Care

The funding comes on the heels of TruLite Health’s recent commercial launch of the Truity platform. This innovative platform zeroes in on systemic clinical bias by delivering multi-level interventions at the point of care. Truity is integrated into the healthcare workflow, and its introduction to the market has sparked significant interest, driving the need for a larger sales, support, and services staff.

See also  Wan Bridge inaugurates Sonata Estates: A new rental experience in Waxahachie, Texas

CEO Alan Roga MD Highlights Commitment to Health Equity

“Addressing systemic clinical bias is paramount for equitable care and improved health outcomes,” said Alan Roga MD, CEO and Co-founder of TruLite Health. “The industry’s positive reception for our Truity platform confirms the urgent need to complement existing Social Determinants of Health (SDoH) initiatives.”

See also  Westrock Coffee begins construction of new RTD facility in Conway

Truity: Powered by World’s Largest Health Equity Knowledge Base

Truity is distinguished by its extensive health equity knowledge base—the world’s largest of its kind. Integrated seamlessly within the Electronic Medical Record (EMR) workflow, the Truity system correlates a patient’s health records and social data sets with this expansive knowledge base. This allows for highly personalized information and recommendations for clinicians and care teams, ultimately filling the gap in most organizations’ health equity strategies.

See also  Alfasigma acquires IBS-C drug Zelnorm from Sloan Pharma

Osage Venture Partners Supports TruLite Health’s Mission

Robert Adelson, Managing Director at Osage Venture Partners, expressed strong support for TruLite Health’s mission and team. “TruLite Health is providing a novel and critically important solution to tackle health equity. Their unique approach in remedying clinical bias at the point of care can revolutionize outcomes for diverse patient populations,” he said. With Osage’s investment, TruLite Health is well-positioned to become a transformative player in the healthcare sector, setting a new standard for health equity and patient care.

CATEGORIES
TAGS
Share This